Newamsterdam Pharma Company N V (NAMSW)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V

Healthcare (1161)

Biotechnology (676)

31 35 206 2971

Gooimeer 2-35, Naarden

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NAMSW's Discussions on Twitter

Vergleichen Sie NAMSW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NAMSW Newamsterdam Pharma Company N V	7.32	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Newamsterdam Pharma Company N V Aktie (NAMSW) Neueste Nachrichten

Finanzdaten der Newamsterdam Pharma Company N V-Aktie (NAMSW)

Es liegen keine Finanzdaten für Newamsterdam Pharma Company N V (NAMSW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Vergleichen Sie NAMSW mit anderen Aktien

Newamsterdam Pharma Company N V Aktie (NAMSW) Neueste Nachrichten

American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan

Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia

Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com Australia

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World

Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada

Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India

Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India

Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com

Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia

Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World

Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex

9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World

A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News

Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia

Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com India

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa

William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World

(NAMS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks

7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga

Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India

Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa

Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks

NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView

Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times

NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey

Finanzdaten der Newamsterdam Pharma Company N V-Aktie (NAMSW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NAMSW